Introduction to Imaging Brain Tumor Metabolism with Positron Emission Tomography (PET)
Author:
- 1 January 1995
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 13 (2) , 244-259
Abstract
The need for prompt and detailed evaluation of cancers and their treatment is requiring increasingly sophisticated methodologies for in vivo assessment. Morphological detail as provided by CT and MRI has yielded significant advances in diagnostic medicine. In spite of such advances, the means of achieving the clinical goals of improved quality and quantity of life in many cancer patients remain elusive. It is becoming increasingly evident that only with the addition of complementary physiological and biochemical data will further advances occur. While neither in vivo morphological imaging with CT or MRI nor physiological imaging with PET or MRS can provide the resolution of microscopic or cellular level assessment, all can provide macroscopic or regional data. With PET, however, exploration of the kinetics or chemical processes occurring at the cellular level is providing a "biological resolution" not heretofore achieved with in vivo imaging. Application of this complementary morphological and biochemical diagnostic information will likely lead to significant advances in patient management in the immediate future, most of which would probably not be achievable using any individual technique. Efficacy studies should be performed, however, when introducing any new high-technology methodology into clinical practice. A number of retrospective and prospective trials on PET applications in clinical oncology are ongoing sponsored by organizations such as the Institute for Clinical PET and the Western PET Association. Detailed studies also are underway to estimate the "cost" of delivery of PET services to the community (146). Numerous PET feasibility studies in animal models have demonstrated that no one radiotracer serves as the best agent for tumor imaging in all cases. Such studies with radiolabeled amino acids, sugars, and nucleoside derivatives, representatives of the major classes of biomolecules, have demonstrated variable tumor uptake dependent on such parameters as the type of cancer, organ of origin, animal host, and chemical structure of the radioligand. Detailed analysis of tracer uptake using multiple ligands in a variety of animal tumor models and clinical patients suggests that while given types of cancers may be better imaged with certain radiotracers, the use of multitracer imaging provides the specific details necessary for appropriate interpretation of tumor status. In addition, in cases where the diagnosis is uncertain, such information could have a significant impact on patient management by reducing the diagnostic differential. In spite of the many successes achieved with FDG in brain tumor imaging, the most well-known example of the problems that can arise with PET image interpretation is with the use of this agent.(ABSTRACT TRUNCATED AT 400 WORDS)Keywords
This publication has 69 references indexed in Scilit:
- Advances in medical imaging for cancer diagnosis and treatmentCancer, 1991
- Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomasJournal of Neuro-Oncology, 1987
- Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study.Radiology, 1987
- Stereotaxic biopsy and positron emission tomography correlation of cerebral gliomasSurgical Neurology, 1987
- Effects of Temporal Sampling, Glucose Metabolic Rates, and Disruptions of the Blood—Brain Barrier on the FDG Model with and without a Vascular Compartment: Studies in Human Brain Tumors with PETJournal of Cerebral Blood Flow & Metabolism, 1986
- Prediction of survival in glioma patients by means of positron emission tomographyJournal of Neurosurgery, 1985
- Positron emission tomography in oncology—The massachusetts general hospital experienceSeminars in Nuclear Medicine, 1985
- Correlation of Experimental and Clinical Studies of Metabolism by PET Scanning1984
- Glucose utilization of cerebral gliomas measured by [ 18 F] fluorodeoxyglucose and positron emission tomographyNeurology, 1982
- Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain.Radiology, 1982